Cover Image
市場調查報告書

炭疽病的開發中產品分析

Anthrax - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 219765
出版日期 內容資訊 英文 142 Pages
訂單完成後即時交付
價格
Back to Top
炭疽病的開發中產品分析 Anthrax - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 142 Pages
簡介

炭疽病是由被稱為炭疽桿菌(bacillus anthracis)的一種細菌所引起的感染疾病。皮膚和消化道、肺是人類主要的感染途徑。炭疽病主要發病於綿羊·牛·山羊等所謂有蹄動物上,但接觸感染的動物的人也有炭疽病發病的危險。以前農夫和獸醫、鞣皮工廠和羊毛工廠的勞工是感染風險最高的族群。炭疽病的症狀依種類不同而有所不同。多數炭疽病患者都使用抗生素治療。

本報告提供全球各國治療炭疽病用的開發中產品開發情形相關分析,彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)進展狀況),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

炭疽病概要

治療藥的開發

  • 炭疽病開發中產品:概要
  • 炭疽病開發中產品:比較分析

各企業正開發中的炭疽病治療藥

大學/研究機關研究中的炭疽病治療藥

開發中產品概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

炭疽病治療藥:開發中產品一覽(各企業)

炭疽病治療藥:研究中產品一覽(大學/研究機關別)

炭疽病治療藥的開發企業

  • Bristol-Myers Squibb Company
  • Aradigm Corporation
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc.
  • Cangene Corporation
  • The Medicines Company
  • Astex Pharmaceuticals, Inc.
  • Oragenics, Inc.
  • Soligenix, Inc.
  • Elusys Therapeutics, Inc.
  • Green Cross Corporation
  • Panacea Biotec Limited
  • Summit Corporation plc
  • Evolva SA
  • MacroGenics, Inc.
  • Vaxin, Inc.
  • Phage Pharmaceuticals, Inc.
  • NanoBio Corporation
  • Immunovaccine, Inc.
  • iBio, Inc.
  • Cellceutix Corporation
  • Tetraphase Pharmaceuticals Inc.
  • Aparna Biosciences Corp.
  • PaxVax
  • Pfenex Inc.
  • SelectX Pharmaceuticals, Inc.
  • Revivicor, Inc.
  • Procarta Biosystems Ltd
  • Innovative Biologics, Inc.
  • PsiOxus Therapeutics, Ltd.
  • Conkwest, Inc.
  • Greffex, Inc.

炭疽病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 分子種類別
  • 各治療分類

藥物簡介

  • Anthrivig
  • NP-015
  • AV-7909
  • GC-1109
  • PreviThrax
  • 基因改造型炭疽病疫苗
  • MDX-1303
  • AVP-21D9
  • ETI-204
  • 炭疽病疫苗
  • ARD-1100
  • MVA-BN炭疽病
  • MU-1140
  • EV-021
  • oritavancin disphosphate
  • CST-102
  • PMX-30016
  • AdVAV炭疽病疫苗
  • Epicutaneous炭疽病疫苗
  • SMT-15000
  • 炭疽病用次單元疫苗
  • 吸入炭疽用單株抗體
  • 炭疽病疫苗
  • 基因改造型防禦抗原炭疽病疫苗
  • TP-271
  • PolyMap
  • 炭疽病膠囊疫苗
  • 疫苗·佐劑
  • DPX-炭疽病疫苗
  • MU-1140-S
  • Metalloproteinase Inhibitors
  • 人抗體為基礎的疫苗
  • 炭疽病·鼠疫併發症的次單元疫苗
  • SGX-204
  • 炭疽病計劃
  • GREANX
  • ABNV-07
  • W1-mAb
  • Epimerox
  • Snare Antibacterial For Anthrax
  • 下一代的炭疽病疫苗
  • KKL-35

炭疽病治療藥:最新的藥物簡介

炭疽病治療藥:暫停開發的產品

炭疽病治療藥:中止開發的產品

炭疽病相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9548IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 24 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anthrax - Overview
    • Anthrax - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Anthrax - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Anthrax - Companies Involved in Therapeutics Development
    • Altimmune Inc
    • Aphios Corp
    • Aradigm Corp
    • Companhia Industrial Produtora de Antibioticos SA
    • ContraFect Corp
    • Crestone Inc
    • Dynavax Technologies Corp
    • Emergent BioSolutions Inc
    • GlaxoSmithKline Plc
    • Green Cross Corp
    • Grifols SA
    • Hawaii Biotech Inc
    • iBio Inc
    • Merck & Co Inc
    • Microbiotix Inc
    • NanoBio Corp
    • PaxVax Inc
    • Pfenex Inc
    • Protein Potential LLC
    • ProThera Biologics Inc
    • Soligenix Inc
    • Syntiron LLC
    • Tetraphase Pharmaceuticals Inc
    • VLP Biotech Inc
  • Anthrax - Drug Profiles
    • anthrax (virus like particles) vaccine - Drug Profile
    • anthrax + plague vaccine - Drug Profile
    • anthrax vaccine - Drug Profile
    • anthrax vaccine - Drug Profile
    • anthrax vaccine - Drug Profile
    • anthrax vaccine - Drug Profile
    • anthrax vaccine - Drug Profile
    • anthrax vaccine - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile
    • ARD-3100 - Drug Profile
    • AV-7909 - Drug Profile
    • BDM-I - Drug Profile
    • CF-306 - Drug Profile
    • CF-307 - Drug Profile
    • CF-308 - Drug Profile
    • ciprofloxacin hydrochloride - Drug Profile
    • CPN-1311 - Drug Profile
    • DPX-Anthrax - Drug Profile
    • DV-230 - Drug Profile
    • epimerox - Drug Profile
    • EV-035 - Drug Profile
    • GC-1109 - Drug Profile
    • gepotidacin mesylate - Drug Profile
    • GREANX - Drug Profile
    • KKL-35 - Drug Profile
    • Marinus - Drug Profile
    • Monoclonal Antibody for Anthrax - Drug Profile
    • Monoclonal Antibody for Anthrax - Drug Profile
    • Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
    • Nasoshield - Drug Profile
    • PBI-220 - Drug Profile
    • Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
    • Protein to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile
    • Px-563L - Drug Profile
    • Px-563L Second Generation - Drug Profile
    • raxibacumab - Drug Profile
    • Recombinant Proteins for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and Anthrax - Drug Profile
    • RiVax + SGX-204 - Drug Profile
    • rPA-01 - Drug Profile
    • RPA-563 - Drug Profile
    • Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile
    • Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile
    • Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile
    • Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
    • Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
    • solithromycin - Drug Profile
    • SparVax - Drug Profile
    • TP-271 - Drug Profile
  • Anthrax - Dormant Projects
  • Anthrax - Discontinued Products
  • Anthrax - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Anthrax, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Anthrax - Pipeline by Altimmune Inc, H2 2017
  • Anthrax - Pipeline by Aphios Corp, H2 2017
  • Anthrax - Pipeline by Aradigm Corp, H2 2017
  • Anthrax - Pipeline by Companhia Industrial Produtora de Antibioticos SA, H2 2017
  • Anthrax - Pipeline by ContraFect Corp, H2 2017
  • Anthrax - Pipeline by Crestone Inc, H2 2017
  • Anthrax - Pipeline by Dynavax Technologies Corp, H2 2017
  • Anthrax - Pipeline by Emergent BioSolutions Inc, H2 2017
  • Anthrax - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Anthrax - Pipeline by Green Cross Corp, H2 2017
  • Anthrax - Pipeline by Grifols SA, H2 2017
  • Anthrax - Pipeline by Hawaii Biotech Inc, H2 2017
  • Anthrax - Pipeline by iBio Inc, H2 2017
  • Anthrax - Pipeline by Merck & Co Inc, H2 2017
  • Anthrax - Pipeline by Microbiotix Inc, H2 2017
  • Anthrax - Pipeline by NanoBio Corp, H2 2017
  • Anthrax - Pipeline by PaxVax Inc, H2 2017
  • Anthrax - Pipeline by Pfenex Inc, H2 2017
  • Anthrax - Pipeline by Protein Potential LLC, H2 2017
  • Anthrax - Pipeline by ProThera Biologics Inc, H2 2017
  • Anthrax - Pipeline by Soligenix Inc, H2 2017
  • Anthrax - Pipeline by Syntiron LLC, H2 2017
  • Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
  • Anthrax - Pipeline by VLP Biotech Inc, H2 2017
  • Anthrax - Dormant Projects, H2 2017
  • Anthrax - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Anthrax - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Anthrax - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Anthrax, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top